For people with vitiligo and their caregivers
What this page helps you do
Learn why narrowband UVB may come up for vitiligo. See how it differs from creams and what to compare before choosing clinic or home care.
- Your task
- Understand the current definition, evidence boundary, practical burden, and questions that affect fit.
- The clinician boundary
- Diagnosis, assessment of activity and body sites, prescribing, monitoring, and personalized treatment decisions belong to a qualified clinician.
When might narrowband UVB enter the conversation?
Narrowband UVB may be discussed when the pattern, activity, extent, body sites, prior treatment, and your goals make light treatment worth considering. It is an option—not an automatic next rung after a topical medicine and not evidence that you failed. Evidence Evidence
Why this matters
Guidelines include narrowband UVB among established clinician-directed vitiligo options and describe its use alone or with selected topical care. The reason for considering it should be stated in terms you understand.
Does moving from a topical to narrowband UVB mean I stop the topical?
Not necessarily. You may need to continue, replace, or combine parts of a plan. That choice depends on the exact medicine, its label, the evidence for the pair, and who coordinates care. Do not make the change from a generic website sequence. Evidence Evidence Evidence
Why this matters
Selected topical-and-light combinations have been studied, including a supervised home-light trial with a topical corticosteroid. Other topical labels contain ultraviolet precautions that must be reconciled before combination.
Will every patch respond the same way?
No. Group evidence shows meaningful differences by body area, and not everyone repigments. A result for the face or neck should not be transferred to hands, feet, or another area. Evidence Evidence
Why this matters
In studied groups, the face and neck generally respond better than hands and feet. “Less responsive” does not mean “never,” and a group average cannot predict one patch.
- Separate a group average from a prediction about one patch.
- Set a realistic goal for each priority area instead of one whole-body promise.
- Ask separately whether the proposed device can practically reach and cover each priority area; that is planning context, not a prediction of biological response.
Should I use a clinic or a home device?
Choosing between clinic and home depends on travel, scheduling, cost, privacy, safety at home, device support, and your care team’s supervision. Home treatment can reduce travel. Owning a device does not make phototherapy self-directed care. Evidence Evidence
Why this matters
Guidelines and clinical research recognize both supervised clinic care and selected home treatment. Each setting changes where training, observation, documentation, and technical support happen.
What should be settled before I begin?
Know the clinical goal and body areas in the plan. Ask which products the team reviewed, who answers safety questions, what to record, and when to review the plan. The device instructions and clinician plan remain your operating sources. Evidence Evidence
Why this matters
Phototherapy guidance emphasizes candidacy, safety review, eye protection, reaction reporting, follow-up, and treatment-specific documentation. A coherent plan also names who coordinates conflicts between a topical label and a light-treatment plan.
Questions that can change the next decision
- For your clinicianWho do I contact about a reaction or conflicting instruction?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- For your clinicianWhat should I record so our review is based on more than memory?Saving keeps this on your device and needs JavaScript, which is off in this browser.
Evidence and update context
This optional layer shows the evidence boundary reviewed for this page as of 2026-08-03.
- What this evidence supports
- Guidelines include narrowband UVB among established clinician-directed vitiligo options and describe its use alone or with selected topical care. The reason for considering it should be stated in terms you understand.
- What it does not establish
- The same diagnosis does not create the same decision for everyone. A clinician must determine candidacy and choose the device; repigmentation remains uncertain.
Applicability check
Who was studied?
These fields show what the cited evidence reports about the people and body sites behind outcome or safety claims. “Not reported” means the reviewed source omitted the field; “Pending exact source review” means SteadySkin has not made that determination yet.
No. Group evidence shows meaningful differences by body area, and not everyone repigments. A result for the face or neck should not be transferred to hands, feet, or another area.
- Age range
- Pending exact source review
- Condition subtype
- Pending exact source review
- Severity or extent
- Pending exact source review
- Sample size
- Pending exact source review
- Geography and care setting
- Pending exact source review
- Skin tone or phototype
- Pending exact source review
- Race
- Pending exact source review
- Ethnicity
- Pending exact source review
- Body sites
- Pending exact source review
What that means for this page: The claim is explicitly gated as body-site evidence, but exact population and site extraction is still pending. It cannot publish or support transfer of one site’s result to another site until that review is complete.
Evidence behind this page
Sources
Each evidence badge opens the source and its limits. The full list stays available here.
- Journal of the European Academy of Dermatology and VenereologyRegulatory / guideline · not independentRelevant relationship disclosed
- Published
- 2023-09-15
- SteadySkin last checked
- 2026-07-31
What this source can and cannot tell you
Why the independence label says this: The journal is the publisher. This label refers to extensive author relationships disclosed for the recommendation, not to the journal itself.
What this source supports
Supports an expert-consensus map of established, off-label and developing Vitiligo treatment categories and makes clear that research is continuing.
What it does not support
It is an international consensus with extensive author relationships, not independent comparative proof, current U.S. regulatory status for every option or a personal treatment sequence.
Automated draft claim mapping withheld from reader-facing evidence details until clinical or editorial review is recorded. This page is not yet approved for indexing.
- DailyMed, U.S. National Library of MedicineRegulatory / guideline · not independentRelevant relationship disclosed
- Published
- 2026-01-28
- SteadySkin last checked
- 2026-07-31
What this source can and cannot tell you
Why the independence label says this: The National Library of Medicine hosts DailyMed. The product company submits the label to FDA, so it is authoritative for product labeling but not independent efficacy evidence.
What this source supports
It establishes the US atopic-dermatitis indication, boxed warning, local effects, long-term-use precaution, and ultraviolet instructions for this product.
What it does not support
It does not approve tacrolimus for vitiligo, establish vitiligo efficacy, or resolve off-label guideline discussion of supervised combinations.
Automated draft claim mapping withheld from reader-facing evidence details until clinical or editorial review is recorded. This page is not yet approved for indexing.
- DailyMed, U.S. National Library of MedicineRegulatory / guideline · not independentRelevant relationship disclosed
- Published
- 2026-04-30
- SteadySkin last checked
- 2026-07-31
What this source can and cannot tell you
Why the independence label says this: The National Library of Medicine hosts DailyMed. The product company submits the label to FDA, so it is authoritative for product labeling but not independent efficacy evidence.
What this source supports
Supports the US atopic-dermatitis indication, boxed warning, application-site effects, long-term-use precaution and instructions to avoid ultraviolet treatment and minimize natural or artificial sunlight.
What it does not support
It does not approve pimecrolimus for vitiligo, establish vitiligo efficacy or resolve off-label guideline discussion of supervised combinations.
Automated draft claim mapping withheld from reader-facing evidence details until clinical or editorial review is recorded. This page is not yet approved for indexing.
- British Journal of Dermatology (Thomas KS, et al.)Clinical research · independentIndependent source
- Published
- 2020-12-28
- SteadySkin last checked
- 2026-07-31
What this source can and cannot tell you
What this source supports
Supports a group-level benefit for the exact supervised topical-corticosteroid and home handheld-light combination studied in active limited vitiligo, alongside minority success, reactions and limited maintenance after treatment ended.
What it does not support
It does not create a general home plan, support other product-device combinations or predict an individual result.
Automated draft claim mapping withheld from reader-facing evidence details until clinical or editorial review is recorded. This page is not yet approved for indexing.
- JAMA Dermatology (Lee JH, et al.)Clinical research · independentIndependent source
- Published
- 2019-05-29
- SteadySkin last checked
- 2026-07-31
What this source can and cannot tell you
What this source supports
Supports pooled group-level repigmentation outcomes for topical calcineurin inhibitors alone and with phototherapy, including variation by body area.
What it does not support
Considerable study heterogeneity limits product-specific and individual inference, and the review does not override current product labels or prove one medicine superior.
Automated draft claim mapping withheld from reader-facing evidence details until clinical or editorial review is recorded. This page is not yet approved for indexing.
- British Journal of Dermatology (Eleftheriadou V, et al.)Regulatory / guideline · independentIndependent source
- Published
- 2022-01-01
- SteadySkin last checked
- 2026-07-31
What this source can and cannot tell you
What this source supports
Supports the clinical history and assessment domains, evaluation of associated autoimmune conditions, its recommendation for thyroid function and antithyroid antibody screening, current classification context, treatment-option map, psychosocial assessment, medical photography and the limits of pediatric evidence.
What it does not support
It was designed for UK care and reviewed literature through May 2019; it does not establish a universal testing plan, prescribe an individual plan, or establish current US labeling or coverage.
Automated draft claim mapping withheld from reader-facing evidence details until clinical or editorial review is recorded. This page is not yet approved for indexing.
- British Journal of Dermatology (Goulden V, et al.)Regulatory / guideline · independentIndependent source
- Published
- 2022-09-01
- SteadySkin last checked
- 2026-07-29
What this source can and cannot tell you
What this source supports
It supports that traditional NB-UVB fluorescent lamps emit a narrow UVB band peaking around 311 nanometres, plus clinical uses, comparisons with other ultraviolet treatments, and safety boundaries including sunburn-type reactions.
What it does not support
It does not provide a personal treatment plan or establish any home-use setting. SteadySkin never reproduces its treatment schedules.
Automated draft claim mapping withheld from reader-facing evidence details until clinical or editorial review is recorded. This page is not yet approved for indexing.